Dataset related to article "Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis)"
Creators
- Gargiulo, Luigi1
- Narcisi, Alessandra1
- Ibba, Luciano1
- Balato, Anna2
- Bianchi, Luca3
- Brianti, Pina4
- Buononato, Dario2
- Burlando, Martina5
- Caldarola, Giacomo6, 7
- Campanati, Anna8
- Campione, Elena3
- Carrera, Carlo G9
- Carugno, Andrea10, 11
- Cristaudo, Antonio12
- Cusano, Francesco13
- Dapavo, Paolo14
- Dattola, Annunziata15
- De Simone, Clara6, 7
- Gaiani, Francesca M16
- Gisondi, Paolo17
- Giunta, Alessandro3
- Loconsole, Francesco18
- Maione, Vincenzo19
- Mortato, Edoardo20
- Marzano, Angelo V9, 21
- Maurelli, Martina17
- Megna, Matteo22
- Mercuri, Santo R4
- Offidani, Annamaria8
- Orsini, Diego23
- Parodi, Aurora24
- Pellacani, Giovanni15
- Potestio, Luca22
- Quaglino, Pietro14
- Richetta, Antonio G15
- Romano, Francesca25
- Sena, Paolo10
- Venturini, Marina26
- Malagoli, Piergiorgio27
- Costanzo, Antonio1, 28
-
1.
IRCCS Humanitas Research Hospital
-
2.
University of Campania "Luigi Vanvitelli"
-
3.
University of Rome Tor Vergata
-
4.
Vita-Salute San Raffaele University
- 5. IRCCS San Martino University Hospital
- 6. Catholic University of the Sacred Heart
-
7.
Agostino Gemelli University Polyclinic
- 8. Università Politecnica delle Marche
-
9.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
10.
Ospedale Papa Giovanni XXIII
- 11. University of Milan-Bicocca
- 12. San Gallicano Dermatological Institute IRCCS
- 13. Gaetano Rummo Hospital
-
14.
University of Turin
-
15.
Sapienza University of Rome
- 16. Azienda Ospedaliera San Donato Milanese
-
17.
University of Verona
-
18.
University of Bari Aldo Moro
- 19. ASST Spedali Civili Hospital
- 20. University of Bari
-
21.
University of Milan
-
22.
University of Naples Federico II
-
23.
San Gallicano Hospital
-
24.
Ospedale Policlinico San Martino
-
25.
Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli
-
26.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
-
27.
IRCCS Policlinico San Donato
-
28.
Humanitas University
Description
Abstract
Introduction: Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited.
Method: This multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score.
Results: The study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study.
Conclusion: Our experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials.
Files
Restricted
The record is publicly accessible, but files are restricted to users with access.
Request access
If you would like to request access to these files, please fill out the form below.
You need to satisfy these conditions in order for this request to be accepted:
This set of raw data is accessible under request because they include sensitive data.
Please provide details about your request
You are currently not logged in. Do you have an account? Log in here
Additional details
Related works
- Is supplemented by
- Publication: 10.3389/fmed.2023.1243843 (DOI)
- Publication: 37614958 (PMID)